In re ACTOS Antitrust Litigati

  1. August 25, 2021

    Takeda Can't Duck Generic-Drug Delay Suit At 2nd Circ.

    The Second Circuit found on Wednesday that Takeda cannot upend a New York federal judge's decision to preserve antitrust claims that it delayed entry of generic alternatives to diabetes treatment Actos, rejecting assertions that the drugmaker was required to list the therapy in a way that broadly extended patent protections.  

  2. April 07, 2021

    2nd Circ. Questions Takeda's 'Lazarus' Take On Drug Patents

    A Second Circuit panel grilled Takeda in oral arguments Wednesday on the pharmaceutical company's bid to duck antitrust claims that it delayed the entry of generic alternatives to diabetes treatment Actos, with one judge likening the company's exclusivity claim to resurrecting "Lazarus from the dead."

  3. October 08, 2020

    Takeda Asks 2nd Circ. To Flip Actos Rulings

    Pharmaceutical firm Takeda urged the Second Circuit in a Wednesday filing to reverse two lower-court decisions that kept alive allegations claiming it delayed the entry of generic alternatives to the diabetes treatment Actos.